Company

Emyria Ltd

ASX:EMD

Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development.

28 stories · page 2 of 2

Pharma & Biotech

Emyria gains ethics approval for landmark MDMA-assisted PTSD therapy trial

By Proactive 08/06/2023

Pharma & Biotech

Emyria completes $2.5M placement to advance MDMA-assisted therapy

By Proactive 01/05/2023

Pharma & Biotech

Emyria expands CBD pipeline with launch of highest potency Ultra-Pure CBD capsule

By Proactive 24/04/2023

Pharma & Biotech

Emyria extends PAX partnership to develop psilocybin-assisted therapy care model

By Proactive 18/04/2023

Pharma & Biotech

Emyria and pharma company Aspen Australia ink agreement to license and commercialise EMD-RX5 as OTC anxiety medication

By Proactive 04/04/2023

Pharma & Biotech

Emyria experiences high patient demand as it enrols for Phase 3 trial of OTC treatment for stress and anxiety

By Proactive 23/03/2023

Pharma & Biotech

Emyria and UWA expand MDMA analogue library to target neurological and mental health conditions

By Proactive 20/03/2023

Pharma & Biotech

Emyria collaborates with psychiatrist-led clinical service in MDMA-assisted therapy for PTSD

By Proactive 07/03/2023